Using Paclitaxel Schedules as Adjuvant Therapy for Breast Cancer
Andrew D. Seidman, MD, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.
Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.
Seidman says that he uses the dose-dense paclitaxel regimen given every two weeks in his practice. This regimen does lend itself to the injection of a growth factor to stimulate white blood cell recovery. This injection has a significant cost and toxicity profile, Seidman says.
Clinical Pearls
The trial found that either the dose-dense paclitaxel administered every two weeks or weekly paclitaxel given over 12 weeks is acceptable.
- Dose-dense paclitaxel (every two weeks) requires the injection of a growth factor to stimulate white blood cell recovery, which has a significant cost and toxicity profile
- The phase III S0221 trial found that either dose-dense paclitaxel administered every two weeks or weekly paclitaxel given over 12 weeks is acceptable
<<<
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
